GRAIL Inc.

AI Score

0

Unlock

18.09
-0.48 (-2.58%)
At close: Jan 14, 2025, 3:59 PM
18.10
0.08%
After-hours Jan 14, 2025, 05:35 PM EST
undefined%
Bid 16.5
Market Cap 607.67M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -58.29
PE Ratio (ttm) -0.31
Forward PE n/a
Analyst Hold
Ask 19.4
Volume 511,079
Avg. Volume (20D) 791,924
Open 18.74
Previous Close 18.57
Day's Range 17.85 - 19.33
52-Week Range 12.33 - 24.92
Beta undefined

About GRAL

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated ...

Sector Healthcare
IPO Date Jun 12, 2024
Employees 1,360
Stock Exchange NASDAQ
Ticker Symbol GRAL

Analyst Forecast

According to 2 analyst ratings, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $16, which is a decrease of -11.53% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
+5.5%
GRAIL shares are trading higher after the company ... Unlock content with Pro Subscription
5 months ago · Source
+3.06%
GRAIL shares are trading higher. The company Q2 financial results.